Home Tags Anti-PD-1/anti-PD-L1

Tag: anti-PD-1/anti-PD-L1

Phase II Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory...

Positive, mature, results from a Phase II study of glembatumumab vedotin (Celldex Therapeutics) in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK...